Business Description
SELLAS Life Sciences Group Inc
NAICS : 325412
SIC : 2834
ISIN : US81642T1007
Description
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.79 | |||||
| Equity-to-Asset | -1.28 | |||||
| Debt-to-Equity | -0.11 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 13.8 | |||||
| 3-Year EPS without NRI Growth Rate | 14.4 | |||||
| 3-Year FCF Growth Rate | -0.6 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 82.67 | |||||
| 9-Day RSI | 72.8 | |||||
| 14-Day RSI | 67.83 | |||||
| 6-1 Month Momentum % | 0.87 | |||||
| 12-1 Month Momentum % | -29.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.23 | |||||
| Quick Ratio | 0.23 | |||||
| Cash Ratio | 0.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -31.1 | |||||
| Shareholder Yield % | -25.31 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -1688.07 | |||||
| ROA % | -225.16 | |||||
| ROIC % | -791.38 | |||||
| ROC (Joel Greenblatt) % | -4985.39 | |||||
| ROCE % | -1456.39 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -2.25 | |||||
| EV-to-EBITDA | -2.25 | |||||
| EV-to-Forward-Revenue | 2.2 | |||||
| EV-to-FCF | -2.71 | |||||
| Earnings Yield (Greenblatt) % | -44.44 | |||||
| FCF Yield % | -36.25 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SELLAS Life Sciences Group Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.263 | ||
| Beta | 1.78 | ||
| Volatility % | 86.73 | ||
| 14-Day RSI | 67.83 | ||
| 14-Day ATR (€) | 0.064221 | ||
| 20-Day SMA (€) | 1.19055 | ||
| 12-1 Month Momentum % | -29.61 | ||
| 52-Week Range (€) | 0.45 - 1.768 | ||
| Shares Outstanding (Mil) | 56.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SELLAS Life Sciences Group Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SELLAS Life Sciences Group Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
SELLAS Life Sciences Group Inc Frequently Asked Questions
What is SELLAS Life Sciences Group Inc(FRA:RXK3)'s stock price today?
The current price of FRA:RXK3 is €1.47. The 52 week high of FRA:RXK3 is €1.77 and 52 week low is €0.45.
When is next earnings date of SELLAS Life Sciences Group Inc(FRA:RXK3)?
The next earnings date of SELLAS Life Sciences Group Inc(FRA:RXK3) is 2024-05-10 Est..
Does SELLAS Life Sciences Group Inc(FRA:RXK3) pay dividends? If so, how much?
SELLAS Life Sciences Group Inc(FRA:RXK3) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers